Matches 1 - 50 out of 115 1 2 3 >


Match Document Document Title
US20120121702 Controlled Release Azithromycin Solid Dosage Forms  
A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
US20150238418 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20150110870 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20150037409 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20110104273 GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE  
Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and...
US20130189356 PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT  
An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a...
US20110150994 Modified Release Formulation  
The invention is directed to the use of an extended release tablet formulation for pramipexole.
US20110287096 MODIFIED GASTRORETENTIVE DRUG DELIVERY SYSTEM FOR AMINE DRUGS  
Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR...
US20120021053 CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION  
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
US20100316710 SUSTAINED-RELEASE TABLET COMPOSITION OF PRAMIPEXOLE  
A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a...
US20140010875 Encased Tamper Resistant Controlled Release Dosage Forms  
In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix...
US20120164220 Encased Tamper Resistant Controlled Release Dosage Forms  
In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix...
US20130108698 Enteric Coated Particles Containing An Active Ingredient  
Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer...
US20110250269 HIGHLY EFFICIENT AND LONG-ACTING SLOW-RELEASE FORMULATION OF POORLY SOLUBLE DRUGS AND PREPARATION METHOD THEREOF  
A high-efficacy, long-acting, slow-release formulation of the poorly soluble drug, comprising solid dispersion of the poorly soluble drug, silica nanoparticles loaded with the poorly soluble drug,...
US20100068267 COMPOSITIONS FOR TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY  
The invention provides methods of treating a cardiovascular disease comprising administering a sustained release formulation of hydralazine hydrochloride and at least one of isosorbide dinitrate...
US20050106249 Once-a-day, oral, controlled-release, oxycodone dosage forms  
Oxycodone formulations are provided which produce substantially flat in vivo steady state plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with...
US20050112200 EDTA containing compositions and uses thereof  
EDTA and EDTA related compositions and methods of using them are described herein. The compositions can have improved bioavailability over EDTA alone. The compositions can be useful in the...
US20100316711 NIFEDIPINE CONTAINING OPRESS COATED TABLET AND METHOD OF PREPARING SAME  
A sustained release nifedipine-containing press coated tablet, which comprises (A) a core comprising nifedipine and a hydrophilic gel-forming high molecular substance, wherein the dissolution of...
US20060057199 Orally disintegrating tablets of atomoxetine  
A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a...
US20070292507 Supportive Treatment of Liver Disease  
The invention provides a composition and method for treatment of a subject suffering from liver disease comprising the oral administration of a slow release formulation of calcium channel blocker...
US20060153908 Spherical pellet formulations  
A process for preparing spherical pellets comprising (a) a water-soluble active ingredient soluble, freely soluble or very soluble in water; and in particular having a water-solubility of ≧0.5...
US20050013859 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt  
The invention provides a solid dosage form, e.g. a tablet, comprising mycophenolic acid or mycophenolate salt and a process for its production.
US20120183612 MATRIX FOR SUSTAINED, INVARIANT AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS  
The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the...
US20050063913 Novel metaxalone compositions  
The present invention is directed to nanoparticulate compositions comprising metaxalone. The metaxalone particles of the composition have an effective average particle size of less than about 2...
US20070036856 Diltiazem controlled release formulation and method of manufacture  
A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8...
US20060204575 Amphetamine formulations  
Amphetamine formulations comprise a plurality of particles comprising two or more pharmaceutically active amphetamine salts, wherein the dosage form, when administered under fed conditions...
US20100092555 SOFT TABLET CONTAINING HIGH MOLECULAR WEIGHT CELLULOSICS  
The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional...
US20140242162 PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN  
The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical...
US20060159744 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof  
The present invention relates to timed dual release dosage forms of short acting hypnotics or salts thereof adapted to release the short acting hypnotic over a predetermined time period, according...
US20050287211 Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition  
The present invention relates to an oral pharmaceutical composition in particle form, which comprises particles that contain a drug at the core of the pharmaceutical composition in particle form;...
US20070292508 ORALLY DISINTEGRATING DOSAGE FORMS  
The present invention is directed to orally disintegrating dosage forms comprising lipid coated substrates and silicified excipients. The use of silicified excipients in the orally disintegrating...
US20100239662 MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION  
Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a...
US20050074493 Extended release formulations of opioids and method of use thereof  
Extended release formulations for the delivery of opioid agonists, including oxycodone, are provided which exhibit low peak to trough plasma concentration fluctuations and sufficiently high plasma...
US20050003004 Pharmaceutical formulation comprising a water-insoluble active agent  
A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar...
US20070003620 Morphine sulfate microgranules, method for preparing same and compositions containing same  
The present invention relates to sustained-release morphine sulfate microgranules each comprising a neutral support grain coated with an active layer and with a sustained-release layer, wherein...
US20090285887 Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor  
A modified release pharmaceutical composition for oral administration comprising plural mini-tablets, comprising a therapeutically effective amount of a Factor Xa inhibitor within a matrix of...
US20090169617 Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix  
A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose,...
US20060177497 Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention  
A controlled-release dosage form is described, which comprises a matrix formed of ingredients (a) and (b): (a) gellan gum, and (b) one or more hydrophilic polymers; and further comprising a drug...
US20090191267 Oral Compositions Containing a Salivation Inducing Agent  
Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto,...
US20100196474 Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic  
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage...
US20050118265 Antifungal oral dosage forms and the methods for preparation  
The present invention relates to pharmaceutical dosage forms which include an antifungal having poor solubility. The pharmaceutical dosage forms of the present invention further comprise...
US20060078614 Taste-masked pharmaceutical compositions  
There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s),...
US20090028941 Pulsatile gastric retentive dosage forms  
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent...
US20100303901 ORAL DELIVERY OF PROTEINS AND PEPTIDES  
Enteric coated capsules or tablets for oral delivery of a protein, polypeptide or peptide drug, in particular for oral delivery of insulin, are provided, comprising microparticles of the protein,...
US20110159093 MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS  
Disclosed herein are multiparticulate modified release pharmaceutical compositions comprising: (a) a first portion comprising an active ingredient, at least one surfactant and at least one release...
US20060246134 Timed, pulsatile release systems  
A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles...
US20060147529 Granulate comprising an oily substance, corresponding production method and tablet  
The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of...
US20100330178 EXTENDED RELEASE COMPOSITIONS COMPRISING AS ACTIVE COMPOUND VENLAFAXINE HYDROCHLORIDE  
The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core,...
US20060275367 Extended release formulations  
The present invention relates to an extended release formulation containing a poorly water soluble active ingredient and to a method for preparing the formulation. The formulation contains a...
US20050118264 Extended release compositions comprising as active compound venlafaxine hydrochloride  
The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core,...

Matches 1 - 50 out of 115 1 2 3 >